Additionally, high levels of THY1/PD-L1 and complement components in T1 tumors provoke an immunosuppressive tumor microenvironment, suggesting an inflammatory phenotype [25], and depletion of C3 in tumor cells enhanced the efficacy of anti–PD-L1 treatment [30]. The gene discussed is CD274; the disease is neoplasm.